BAX vs LUNG

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

BAX

62.1
AI Score
VS
LUNG Wins

LUNG

66.6
AI Score

Investment Advisor Scores

BAX

62score
Recommendation
BUY

LUNG

67score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BAX LUNG Winner
Revenue 5.66B 43.34M BAX
Net Income 111.00M -23.73M BAX
Gross Margin 34.0% 78.0% LUNG
Net Margin 2.0% -54.8% BAX
Operating Income 283.00M -22.01M BAX
ROE 1.8% -60.6% BAX
ROA 0.6% -20.7% BAX
Total Assets 19.79B 114.73M BAX
Cash 2.15B 55.84M BAX
Current Ratio 1.95 4.32 LUNG

Relative Price Performance (Last 90 Days)

BAX 1M: -7.2% · 3M: +4.4% LUNG 1M: -14.7% · 3M: +37.4%

Current Technical Phase

BAX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 43

RSI (14): 43.5 · Price: $23.64

LUNG

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 44.0 · Price: $1.91

Fundamentals Snapshot

Metric BAX LUNG
Market Cap — —
Forward P/E 11.6 -2.0
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.1% 0.0%
Gross Margin 0.3% 0.8%
Operating Margin 0.1% -0.4%
EPS -1.92 -1.15
Dividend Yield 0.01% —

Frequently Asked Questions

Based on our detailed analysis, LUNG is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.